Toxicity marker for 5-fluorouracil
AssigneesOxford University Innovation Limited, The Universtiy of Birmingham
InventorsClaire Palles, David Kerr, Rachel Kerr
Life of this patent
Estimating the term…
Abstract
The invention relates to an assay. More specifically, the invention relates to an assay for predicting cardiovascular toxicity of a chemotherapeutic agent.
Claims14
A method of screening for risk of 5-fluorouracil (5FU)-induced cardiovascular toxicity in a patient, comprising screening the patient for the presence of rs4904753 or a functionally equivalent variant thereof, wherein:
- (i) the presence of rs4904753 or a functionally equivalent variant thereof indicates an increased risk of developing 5FU-induced cardiovascular toxicity compared to a patient which does not possess rs4904753 or a functionally equivalent variant thereof;
- and
- (ii) the absence of rs4904753 or a functionally equivalent variant thereof indicates no increased risk or a decreased risk of developing 5FU-induced cardiovascular toxicity compared to a patient which possesses rs4904753 or a functionally equivalent variant thereof.
The method according to any one of the preceding claims, wherein the patient has been identified as a candidate for chemotherapy with 5FU, optionally wherein the patient has been identified as a candidate for chemotherapy with capecitabine.
The method according to any one of the preceding claims, wherein the patient is undergoing chemotherapy with 5FU, optionally wherein the patient is undergoing chemotherapy with capecitabine.
The method according to any one of the preceding claims, wherein the screening is carried out on a fluid sample from the patient.
The method according to any one of the preceding claims, wherein the screening is carried out on a solid sample from the patient.
The method according to any one of the preceding claims, wherein in the absence of rs4904753 or a functionally equivalent variant thereof, the method further comprises identifying the patient as a candidate for chemotherapy with 5FU or a prodrug thereof, optionally wherein the prodrug is capecitabine.
The method according to any one of the preceding claims, wherein in the presence of rs4904753 or a functionally equivalent variant thereof, the patient is identified as a candidate for chemotherapy which does not comprise administration of 5FU or a prodrug thereof, such as capecitabine.
The method according to any one of the preceding claims, wherein in the presence of rs4904753 or a functionally equivalent variant thereof, the method further comprises monitoring the patient for one or more symptoms of cardiovascular toxicity during and/or after treatment with 5FU, or a prodrug thereof.
Dependencies are inferred from the claim text.